Juan Domingo Gispert
Overview
Explore the profile of Juan Domingo Gispert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
2805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cacciaglia R, Falcon C, Benavides G, Brugulat-Serrat A, Aloma M, Calvet M, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e14415.
PMID: 39898436
Introduction: Identifying the link between early Alzheimer's disease (AD) pathological changes and neurodegeneration in asymptomatic individuals may lead to the discovery of preventive strategies. We assessed longitudinal brain atrophy and...
2.
Genius P, Calle M, Rodriguez-Fernandez B, Minguillon C, Cacciaglia R, Garrido-Martin D, et al.
Alzheimers Dement
. 2025 Jan;
21(2):e14490.
PMID: 39868465
Introduction: Traditional multivariate methods for neuroimaging studies overlook the interdependent relationship between brain features. This study addresses this gap by analyzing relative brain volumetric patterns to capture how Alzheimer's disease...
3.
Cacciaglia R, Shekari M, Salvado G, Mila-Aloma M, Falcon C, Sanchez-Benavides G, et al.
Brain Commun
. 2024 Dec;
7(1):fcae451.
PMID: 39723106
CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and...
4.
Buongiorno M, Sanchez-Benavides G, Marzal-Espi C, Giraldo D, Krupinski J, Cullell N, et al.
J Alzheimers Dis
. 2024 Nov;
102(4):975-980.
PMID: 39584306
β-blockers that easily cross the blood-brain barrier (BBB) seem to diminish the risk of Alzheimer's disease (AD), hypothetically facilitating waste clearance. However, their effect on AD pathophysiological markers is unknown....
5.
Collij L, Bollack A, La Joie R, Shekari M, Bullich S, Roe-Vellve N, et al.
Alzheimers Dement
. 2024 Nov;
20(12):9037-9048.
PMID: 39564918
Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium...
6.
Collij L, Bischof G, Altomare D, Bader I, Battle M, Garcia D, et al.
J Nucl Med
. 2024 Nov;
66(1):110-116.
PMID: 39542700
Several studies have demonstrated strong agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support assessment by less experienced readers or in challenging cases. However, all...
7.
8.
Vila-Castelar C, Akinci M, Palpatzis E, Aguilar-Dominguez P, Operto G, Kollmorgen G, et al.
Mol Psychiatry
. 2024 Oct;
PMID: 39384963
Glial reactivity may contribute to sex/gender differences in Alzheimer's disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by...
9.
Tristao-Pereira C, Fuster V, Lopez-Jimenez A, Fernandez-Pena A, Semerano A, Fernandez-Nueda I, et al.
Am Heart J
. 2024 Sep;
278:195-207.
PMID: 39322173
Rationale: Cognitive decline and dementia have been reportedly linked to atherosclerosis, the main cause of cardiovascular disease. Cohort studies identifying early brain alterations associated with subclinical atherosclerosis are warranted to...
10.
Lorenzini L, Maranzano A, Ingala S, Collij L, Tranfa M, Blennow K, et al.
Neurology
. 2024 Sep;
103(7):e209801.
PMID: 39288341
Background And Objectives: Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk...